2m 2m 2m 2m 2m 2m 2m
JUPITER NEUROSCN (JUNS)
NASDAQ
$0.24+$0.004 (+1.69%)
Price as of Jun 23, 2026 7:59 PM EDT- $10.0MMarket Cap
- -79.12%1-Year Change
- BiotechnologyIndustry
JUPITER NEUROSCN (JUNS)
$0.24+$0.004 (+1.69%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 21,796 N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 17,565 N/A | 0 N/A | |
Sales and Marketing Expense | 817,554 N/A | N/A N/A | |
Research and Development Expense | N/A N/A | -492,660 N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | 8.9M +188.76% | 3.1M N/A | |
Operating Profit | -8.9M +188.19% | -3.1M N/A | |
Interest Income | N/A N/A | 5,557 N/A | |
Interest Expense | -1,064 0.00% | -1,064 N/A | |
Interest Income and Expense and Net | -1,064 -123.68% | 4,493 N/A | |
Total Nonoperating Income and Expense | 47,912 -92.65% | 651,657 N/A | |
Income before Taxes | -8.9M +188.19% | -3.1M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | N/A N/A | N/A N/A | |
Net Income from Continuing Operations Applicable to Common | N/A N/A | N/A N/A | |
Basic EPS and Net Income | -0.25 +212.50% | -0.08 N/A | |
Diluted EPS and Net Income | -0.25 +212.50% | -0.08 N/A | |
Basic Weighted Average Shares | 34.6M +20.31% | 28.8M N/A | |
Diluted Weighted Average Shares | 34.6M +20.31% | 28.8M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 3.8M +0.53% | 3.8M N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 3.8M +0.53% | 3.8M N/A | |
Total Current Assets | 4.8M +3.76% | 4.7M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | 3,783 0.00% | 3,783 N/A | |
Total Assets | 5.6M -10.29% | 6.2M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 5.3M +3,518.11% | 146,432 N/A | |
Total Current Liabilities | 7.4M +268.11% | 2.0M N/A | |
Total Long-Term Debt | 4.2M +102.48% | 2.1M N/A | |
Total Long-Term Liabilities | 21,247 0.00% | 21,247 N/A | |
Total Liabilities | 7.4M +264.26% | 2.0M N/A | |
Retained Earnings | -34.7M +33.22% | -26.0M N/A | |
Total Stockholders Equity | N/A N/A | 4.2M N/A | |
Total Shares Outstanding | 34.4M +4.06% | 33.1M N/A | |
Cash Flow | |||
Cash from Operating Activities | -5.4M +38.42% | -3.9M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 5.4M -28.99% | 7.7M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -40,873.19% N/A | N/A N/A | |
Return on Assets | N/A N/A | N/A N/A | |
Return on Equity | N/A N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 0.65 N/A | N/A N/A | |
Cash Ratio | 0.51 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 1.70 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow